Helsel Dave 4
4 · ANGIODYNAMICS INC · Filed Jul 11, 2022
Insider Transaction Report
Form 4
Helsel Dave
SVP Global Operations and R&D
Transactions
- Exercise/Conversion
Performance Right
2022-07-07−6,945→ 0 total→ Common Stock (6,945 underlying) - Exercise/Conversion
Common Stock
2022-07-07+3,480→ 26,354 total - Tax Payment
Common Stock
2022-07-07$20.54/sh−1,223$25,120→ 25,131 total
Footnotes (3)
- [F1]This acquisition of 3,480 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.
- [F2]The exempt disposition of 1,223 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.
- [F3]On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,480 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.